{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:11:05Z","timestamp":1792390265959,"version":"4.4.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2011,11,7]],"date-time":"2011-11-07T00:00:00Z","timestamp":1320624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To evaluate the performance of 6-O-Lauryl\u2013\n                      <jats:sc>l<\/jats:sc>\n                      -ascorbic acid nanostructures (coagels) as vehicles for acetazolamide (AZM) in ophthalmic administration by\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      experimental tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The systems of coagel + AZM were evaluated in terms of their\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      release (dialysis membrane), permeability (isolated cornea), pharmacological effectiveness [intraocular pressure (IOP)-reduction in normotensive rabbits], and potential irritant effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The results concerning AZM permeation were better when vehiculized in coagels compared with ringer solution, which was evident from the AZM steady-state flux and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      <jats:sub>app<\/jats:sub>\n                      values (\n                      <jats:italic toggle=\"yes\">J<\/jats:italic>\n                      =1.43\u2009\u03bcg\/min and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      <jats:sub>app<\/jats:sub>\n                      =3.04\u2009cm.s\n                      <jats:sup>1<\/jats:sup>\n                      ). As a consequence of this increase in permeation, the coagel-AZMs were more effective in lowering the IOP, according to the results obtained from the\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      assays. Coagels loaded with 0.4% (W\/W) of AZM showed a higher hypotensive effect in rabbits compared with the commercial formulation AZOPT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (brinzolamide 1%), mainly due to the prolonged effect of the former. In all cases, the intensity of irritation was time dependent. The sodium lauryl sulphate solution (2%) used as a positive control produced serious injury 30\u2009min postadministration. This effect caused irritation, which decreased slowly and even at 180\u2009min, the discomfort was still considerable. However, in the case of coagels, a mild-to-moderate effect was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The incorporation of AZM in coagels seems to improve the ocular bioavailability of this drug. Coagel-AZM 0.4% showed a higher hypotensive effect, with a mild-to-moderate irritant effect. These systems could be administrated in human beings, although more detailed studies still need to be carried out.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2011.0104","type":"journal-article","created":{"date-parts":[[2011,11,7]],"date-time":"2011-11-07T16:29:00Z","timestamp":1320683340000},"page":"102-109","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Improvement of Acetazolamide Ocular Permeation Using Ascorbyl Laurate Nanostructures as Drug Delivery System"],"prefix":"10.1177","volume":"28","author":[{"given":"Luis I.","family":"T\u00e1rtara","sequence":"first","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela A.","family":"Quinteros","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Saino","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Allemandi","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago D.","family":"Palma","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,11,7]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2006.07.027"},{"key":"e_1_3_3_3_2","first-page":"328","article-title":"Recent developments in ophthalmic drug delivery","volume":"1","author":"Shulin D.","year":"1998","unstructured":"Shulin D. Recent developments in ophthalmic drug delivery. PSSP, 1:328\u2013335. 1998.","journal-title":"PSSP"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2006.02.050"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(99)00192-3"},{"key":"e_1_3_3_6_2","first-page":"159","article-title":"Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface","volume":"224","author":"De Campos A.M.","year":"2001","unstructured":"De Campos A.M., , S\u00e1nchez A., , Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm., 224:159\u2013168. 2001.","journal-title":"Application to cyclosporin A. Int. J. Pharm."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(02)00080-7"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2008.12.018"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(97)00199-3"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2009.04.035"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(97)00419-5"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2009.01.001"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1475-1313.1998.00364.x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2007.06.002"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(02)00438-6"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00158a028"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0927-7757(99)00465-3"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/la026042d"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-011-2272-6"},{"key":"e_1_3_3_20_2","volume-title":"Surfactant Science and Technology","author":"Myers D.","year":"1994","unstructured":"Myers D. Surfactant Science and Technology. New York: VCH, 1994."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/la960271g"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1006\/jcis.1996.4646"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1006\/jcis.1996.4646"},{"key":"e_1_3_3_24_2","volume-title":"Estudio de compuestos anfif\u00edlicos y su utilizaci\u00f3n en tecnolog\u00eda farmac\u00e9utica","author":"Palma S.","year":"2003","unstructured":"Palma S. Estudio de compuestos anfif\u00edlicos y su utilizaci\u00f3n en tecnolog\u00eda farmac\u00e9uticaPh.D. ThesisC\u00f3rdoba, Argentina: Universidad Nacional de C\u00f3rdoba, 2003."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1139\/v81-366"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/03639040500534150"},{"key":"e_1_3_3_27_2","first-page":"15","article-title":"Acetazolamida de Aplicaci\u00f3n T\u00f3pica: Estudios Preliminares","volume":"2","author":"T\u00e1rtara L.I.","year":"2007","unstructured":"T\u00e1rtara L.I., , Quinteros D.A., , Saino V. et al. Acetazolamida de Aplicaci\u00f3n T\u00f3pica: Estudios Preliminares. Oftalmolog\u00eda Cl\u00ednica y Experimental, 2:15\u201318. 2007.","journal-title":"Oftalmolog\u00eda Cl\u00ednica y Experimental"},{"key":"e_1_3_3_28_2","first-page":"335","article-title":"An in vitro model for determination of drug permeability through the cornea","volume":"22","author":"Camber O.","year":"1985","unstructured":"Camber O. An in vitro model for determination of drug permeability through the cornea. Acta. Pharm., 22:335\u2013342. 1985.","journal-title":"Acta. Pharm."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)08751-8"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1039\/B314061J"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1021\/la026807h"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-69222-2_2"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015802427428"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.4155\/tde.10.40"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2011.0104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2011.0104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2011.0104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:37:11Z","timestamp":1777646231000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2011.0104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,7]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4,1]]}},"alternative-id":["10.1089\/jop.2011.0104"],"URL":"https:\/\/doi.org\/10.1089\/jop.2011.0104","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,7]]}}}